Strong Xtandi Drives Astellas To Brighter Outlook
Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.
You may also be interested in...
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.
Astellas has exercised an option to acquire Potenza, paying up to $404.7m in cash for the private US venture in a deal that will boost its presence in immuno-oncology.
First nod globally for Astellas's FLT3 inhibitor set to further increase competition in AML space, but commercial opportunity in launch market Japan looks set to be limited.